Zur Rose gets approval to go public
Frauenfeld TG – The online pharmacy Zur Rose can realise its plans to go public after its shareholders approved the corresponding proposals from the Board of Directors at an extraordinary general meeting.
Zur Rose shareholders approved two proposals necessary for a stock exchange listing by a large majority at the general meeting, according to a statement. The first is the creation of authorised share capital with a nominal value of CHF 12,474,159.25, which corresponds to 50 per cent of the existing share capital. The second is a complete revision of the Articles of Association required for an initial public offering (IPO).
The online pharmacy from the St.GallenBodenseeArea plans to use the stock exchange listing “to better exploit the growth opportunities in the market to further expand its strong position in the European pharmaceutical e-commerce sector”.
Zur Rose sees two particular drivers of growth. First, the aging populations in the Swiss and German markets via the Zur Rose and DocMorris brands respectively. Second, digitalisation in the healthcare sector lags behind other consumer goods industries, thus creating growth opportunities.
The revised Articles of Association will become effective only upon completion of the capital increase as part of an IPO on the SIX Swiss Exchange.